EUVIMEDEUVIMED entdecken
Crossref

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma

Salah Eddine O Kacimi iD, Caroline Dehais iD, Loïc Feuvret iD, Olivier Chinot iD, Catherine Carpentier, Charlotte Bronnimann, Elodie Vauleon, Apolline Djelad, Elizabeth Cohen-Jonathan Moyal iD, Olivier Langlois iD, Mario Campone, Mathilde Ducloie iD und 30 weitere

Journal of Clinical Oncology · 20.01.2025 · 43 (3) · 329-338

DOI: 10.1200/jco.24.00049 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.01.2025. Verfasst von Salah Eddine O Kacimi und 41 weiteren Autor:innen. Beteiligte Einrichtung: Institut du Cerveau, Paris Brain Institute (ICM), Inserm, CNRS, Sorbonne Université, AP-HP, SIRIC CURAMUS, Paris, France. Hauptthemen laut MEDLINE: Oligodendroglioma, Brain Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Isocitrate Dehydrogenase. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Patients with IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma (O3 IDHmt/Codel ) benefit from adding alkylating agent chemotherapy to radiotherapy (RT). However, the optimal chemotherapy regimen between procarbazine, 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), and vincristine (PCV) and temozolomide (TMZ) remains unclear given the lack of randomized trial data comparing both regimens. METHODS The objective was to assess the overall survival (OS) and progression-free survival (PFS) associated with first-line PCV/RT versus TMZ/RT in patients newly diagnosed with O3 IDHmt/Codel . We included patients with histologically proven O3 IDHmt/Codel (according to WHO criteria) from the French national prospective cohort Prise en charge des OLigodendrogliomes Anaplasiques (POLA). All tumors underwent central pathologic review. OS and PFS from surgery were estimated using the Kaplan-Meier method and Cox regression model. RESULTS 305 newly diagnosed patients with O3 IDHmt/Codel treated with RT and chemotherapy between 2008 and 2022 were included, of which 67.9% of patients (n = 207) were treated with PCV/RT and 32.1% with TMZ/RT (n = 98). The median follow-up was 78.4 months (IQR, 44.3-102.7). The median OS was not reached (95% CI, Not reached [NR] to NR) in the PCV/RT group and was 140 months (95% CI, 110 to NR) in the TMZ/RT group (log-rank P = .0033). On univariable analysis, there was a significant difference in favor of PCV/RT in both 5-year (PCV/RT: 89%, 95% CI, 85 to 94; TMZ/RT: 75%, 95% CI, 66 to 84) and 10-year OS (PCV/RT: 72%, 95% CI, 61 to 85; TMZ/RT: 60%, 95% CI, 49 to 73), which was confirmed using the multivariable Cox model adjusted for age, type of surgery, gender, Eastern Cooperative Oncology Group performance status, and CDKN2A homozygous deletion (hazard ratio, 0.53 for PCV/RT, 95% CI, 0.30 to 0.92, P = .025). CONCLUSION In patients with newly diagnosed O3 IDHmt/Codel from the POLA cohort, first-line PCV/RT was associated with better OS outcomes compared with TMZ/RT. Our data suggest that the improved safety profile associated with TMZ comes at the cost of inferior efficacy in this population. Further investigation using prospective randomized studies is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OligodendrogliomaBrain NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsIsocitrate DehydrogenaseChemoradiotherapyHumansTemozolomideProcarbazineMaleFemaleVincristineMiddle AgedLomustineAdultMutationAgedChromosomes, Human, Pair 1Neoplasm GradingChromosomes, Human, Pair 19Progression-Free SurvivalYoung AdultProspective Studies

Substanzen

TemozolomideProcarbazineVincristineLomustineIsocitrate Dehydrogenase

Autor:innen und Institutionen

  • Institut du Cerveau, Paris Brain Institute (ICM), Inserm, CNRS, Sorbonne Université, AP-HP, SIRIC CURAMUS, Paris, France.
  • Sorbonne Université, CinBioS, UMS 37 PASS, INSERM, Paris, France.
  • Service de Neuro-oncologie, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, AP-HP, Sorbonne Université, Paris, France.
  • Hospices Civils de Lyon, Radiotherapy Department, Bron, France.
  • Department of Neuro-Oncology, Aix-Marseille Université, CHU Timone, AP-HM, Marseille, France.
  • Department of Medical Oncology, University Hospital of Bordeaux, Bordeaux, France.

ORCID-Profile: Salah Eddine O Kacimi, Caroline Dehais, Loïc Feuvret, Olivier Chinot, Elizabeth Cohen-Jonathan Moyal, Olivier Langlois, Mathilde Ducloie, Georges Noel, Stefania Cuzzubbo, Veronique Bourg, Emeline Tabouret, Lucia Nichelli, Franck Bielle, Agusti Alentorn, J Bryan Iorgulescu, Pierre-Yves Boëlle, Ahmed Idbaih, Dominique Figarella-Branger, Mehdi Touat

Zitieren

APA

Kacimi, S. E. O., Dehais, C., Feuvret, L., Chinot, O., Carpentier, C., Bronnimann, C., Vauleon, E., Djelad, A., Cohen-Jonathan Moyal, E., Langlois, O., Campone, M., Ducloie, M., Noel, G., Cuzzubbo, S., Taillandier, L., Ramirez, C., Younan, N., Menei, P., Dhermain, F., …, & POLA Network (2025). Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma. Journal of Clinical Oncology, 43(3), 329-338. https://doi.org/10.1200/jco.24.00049

Vancouver

Kacimi SEO, Dehais C, Feuvret L, Chinot O, Carpentier C, Bronnimann C, et al. Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma. Journal of Clinical Oncology. 2025;43(3):329-338. doi:10.1200/jco.24.00049

BibTeX
@article{Kacimi2025,
  author = {Kacimi, Salah Eddine O and Dehais, Caroline and Feuvret, Loïc and Chinot, Olivier and Carpentier, Catherine and Bronnimann, Charlotte and Vauleon, Elodie and Djelad, Apolline and Cohen-Jonathan Moyal, Elizabeth and Langlois, Olivier and Campone, Mario and Ducloie, Mathilde and Noel, Georges and Cuzzubbo, Stefania and Taillandier, Luc and Ramirez, Carole and Younan, Nadia and Menei, Philippe and Dhermain, Frédéric and Desenclos, Christine and Ghiringhelli, François and Bourg, Veronique and Ricard, Damien and Faillot, Thierry and Appay, Romain and Tabouret, Emeline and Nichelli, Lucia and Mathon, Bertrand and Thomas, Alice and Tran, Suzanne and Bielle, Franck and Alentorn, Agusti and Iorgulescu, J Bryan and Boëlle, Pierre-Yves and Labreche, Karim and Hoang-Xuan, Khê and Sanson, Marc and Idbaih, Ahmed and Figarella-Branger, Dominique and Ducray, François and Touat, Mehdi and POLA Network, POLA Network},
  title = {Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {3},
  pages = {329--338},
  doi = {10.1200/jco.24.00049}
}
Kostenlos starten →